2016 ISHLT Annual Meeting and Scientific Sessions

Apr 27, 2016 ‐ Apr 30, 2016


Standard: $250.00

Sessions

PRE-MEETING SYMPOSIUM 01: Anticoagulation and MCS: Can We Do Better? -- Is There a Role for Antiplatelet Monitoring in MCS?

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:35am

Identification: PMSY01e

The goal of this symposium is to familiarize clinicians with current, widely available tests of blood coagulability and pitfalls in their interpretation in the MCS population. Additional topics will include comorbid states, such as acquired von Willebrand’s disease and genetic variations like Factor V mutations, and how they impact patients after device implantation.

Speaker(s):

PRE-MEETING SYMPOSIUM 02: Controversies in Heart Transplantation: Past, Present and Future -- The Future of Heart Transplant Immunosuppression: Something's Old, Something's New, Something's Borrowed, Somebody's Blue Systems, Not Time O

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:40am

Identification: PMSY02g

This session will review current immunosuppressant pharmacology as well as the current status of rejection surveillance. The utility of endomyocardial biopsy will be debated and then a report on future of heart transplant immunosuppression will be presented including perspectives on where the next advances will come from.

Speaker(s):
  • David Baran, MD, Sentara Heart Hospital, Norfolk, VA, United States

PRE-MEETING SYMPOSIUM 03: Current Innovations and Future of EVLP -- Is Reduced Allo Responsiveness after EVLP a Reality? - Long Term Follow Up

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:35am

Identification: PMSY03e

This symposia will explore the prospect of gene, cell, drug and molecular interventions during EVLP to improve outcomes for lung transplant recipients. How essential EVLP is to the running of a modern day program will be debated.

Speaker(s):

PRE-MEETING SYMPOSIUM 04: Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease -- Impact of PH on Transplant Outcomes in ILD

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:35am

Identification: PMSY04e

Cardiothoracic transplantation for patients with HIV, and hepatitis B and C remains a controversial topic. Historically, infection with any of these viruses was considered a relative or even absolute contraindication for transplantation. However, favorable experience in liver and kidney recipients has led some programs to progressively adjust selection criteria. The recent ISHLT listing criteria guidelines now include HIV, HCV and HBV positive patients and more programs are performing transplantation in these complex populations. Having a current understanding of these diseases, therapy and monitoring will assist the transplant team.  This includes knowledge of drug interactions and the concerns for the various types of  immunosuppression (Induction, maintenance) on these patients and if there are preferred agents to use.  Lastly developing an approach with an understanding of how to manage complications is necessary for success. Therefore, the focus of this symposium is to increase the knowledge of the CT transplant community about the management and pharmacological treatment options for CT transplants candidates with HIV, hepatitis B or C, before and after transplant.

Speaker(s):

PRE-MEETING SYMPOSIUM 05: Making It Work: Heart Transplant Challenges from the Surgeon's Perspective -- Advanced Plumbing: How to Manage Complex Connections in Adult Congenital Heart Transplant Recipients

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:40am

Identification: PMSY05e

To discuss the controversies, advances, and new directions in heart transplant surgery.

Speaker(s):

PRE-MEETING SYMPOSIUM 06: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant? -- Stem Cells to Cure the Incurable: Treatment for Chronic Lung and Heart Allograft Dysfunction

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:35am

Identification: PMSY06e

This session will focus on cutting edge therapies that involve cells. There will be a focus on using cells to repair or fully regenerate a failing organ, for transplant tolerance induction or treatment of chronic rejection.

Speaker(s):
  • Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, United States

PRE-MEETING SYMPOSIUM 07: The Future is Here: Emerging Issues in Infectious Disease -- Running Away With It: C. difficile and Norovirus

Apr 27, 2016 9:20am ‐ Apr 27, 2016 9:35am

Identification: PMSY07e

This symposium will explore the emergence and resurgence of difficult to treat pathogens in thoracic transplant and MCSD patients that challenge practitioners worldwide.

Speaker(s):

PRE-MEETING SYMPOSIUM 01: Anticoagulation and MCS: Can We Do Better? -- Alternative Approaches to Recurrent Bleeding - Octreotide, Hormonal Therapy, Etc.

Apr 27, 2016 9:40am ‐ Apr 27, 2016 9:55am

Identification: PMSY01f

The goal of this symposium is to familiarize clinicians with current, widely available tests of blood coagulability and pitfalls in their interpretation in the MCS population. Additional topics will include comorbid states, such as acquired von Willebrand’s disease and genetic variations like Factor V mutations, and how they impact patients after device implantation.

Speaker(s):
  • Nir Uriel, MD, MSc, University of Chicago, Chicago, IL, United States

PRE-MEETING SYMPOSIUM 04: Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease -- Are PAH Specific Therapies Beneficial in PH-ILD?

Apr 27, 2016 9:40am ‐ Apr 27, 2016 9:55am

Identification: PMSY04f

Cardiothoracic transplantation for patients with HIV, and hepatitis B and C remains a controversial topic. Historically, infection with any of these viruses was considered a relative or even absolute contraindication for transplantation. However, favorable experience in liver and kidney recipients has led some programs to progressively adjust selection criteria. The recent ISHLT listing criteria guidelines now include HIV, HCV and HBV positive patients and more programs are performing transplantation in these complex populations. Having a current understanding of these diseases, therapy and monitoring will assist the transplant team.  This includes knowledge of drug interactions and the concerns for the various types of  immunosuppression (Induction, maintenance) on these patients and if there are preferred agents to use.  Lastly developing an approach with an understanding of how to manage complications is necessary for success. Therefore, the focus of this symposium is to increase the knowledge of the CT transplant community about the management and pharmacological treatment options for CT transplants candidates with HIV, hepatitis B or C, before and after transplant.

Speaker(s):
  • Steven Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, United States

PRE-MEETING SYMPOSIUM 03: Current Innovations and Future of EVLP -- DEBATE: My Clinical Program Needs an EVLP Service (PRO)

Apr 27, 2016 9:40am ‐ Apr 27, 2016 9:50am

Identification: PMSY03f

This symposia will explore the prospect of gene, cell, drug and molecular interventions during EVLP to improve outcomes for lung transplant recipients. How essential EVLP is to the running of a modern day program will be debated.

Speaker(s):
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content